logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2- metastatic breast cancer: improved PFS but not OS with bevacizumab+chemo: meta-analysis

Meta-analysis of 8 RCTs shows a 28% improvement in PFS.